Volume | 1,382,491 |
|
|||||
News | (5) | ||||||
Day High | 446.10 | Low High |
|||||
Day Low | 440.33 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vertex Pharmaceuticals Inc | VRTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
442.00 | 440.33 | 446.10 | 445.21 | 440.64 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
31,284 | 1,382,491 | $ 442.83 | $ 612,210,494 | - | 320.01 - 448.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:51:08 | 9 | $ 445.40 | USD |
Vertex Pharmaceuticals (VRTX) Options Flow Summary
Vertex Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
115B | 258.31M | - | 9.92B | 3.57B | 13.82 | 32.21 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vertex Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 420.67 | 446.10 | 417.50 | 432.26 | 1,043,058 | 24.54 | 5.83% |
1 Month | 394.72 | 446.10 | 391.25 | 409.66 | 1,118,934 | 50.49 | 12.79% |
3 Months | 430.00 | 446.10 | 391.01 | 411.23 | 1,019,707 | 15.21 | 3.54% |
6 Months | 346.26 | 448.40 | 342.64 | 408.12 | 1,280,508 | 98.95 | 28.58% |
1 Year | 343.90 | 448.40 | 320.01 | 380.34 | 1,232,152 | 101.31 | 29.46% |
3 Years | 215.62 | 448.40 | 176.36 | 284.39 | 1,504,779 | 229.59 | 106.48% |
5 Years | 168.90 | 448.40 | 165.23 | 260.37 | 1,543,215 | 276.31 | 163.59% |
Vertex Pharmaceuticals Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |